+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immunotherapy Drugs Market - Global Forecast 2026-2032- Product Image
Immunotherapy Drugs Market - Global Forecast 2026-2032- Product Image
New

Immunotherapy Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 183 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5889000
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immunotherapy drugs market is redefining oncology, presenting industry leaders with evolving challenges and opportunities driven by ongoing scientific breakthroughs and shifting regulatory and commercial landscapes. As innovation reshapes how therapies are developed and delivered, stakeholders must realign strategies to capture growth and optimize patient outcomes.

Market Snapshot: Immunotherapy Drugs Market Growth

The global immunotherapy drugs market is forecast to grow from USD 222.59 billion in 2025 to USD 251.56 billion by 2026. Propelled by steady demand and robust advancement in research pipelines, the sector is projected to reach USD 543.82 billion by 2032, reflecting a compound annual growth rate (CAGR) of 13.61%. Key drivers include expanding treatment options and increasing adoption across multiple oncologic indications, making immunotherapy a pivotal focus across provider organizations, pharmaceutical manufacturers, and payers worldwide.

Scope & Segmentation

  • Therapy Platforms: Encompasses adoptive cell therapies (including autologous and allogeneic; CAR-T, NK cell, TCR-T technologies), a range of cancer vaccines (peptide, dendritic cell, DNA), checkpoint inhibitors (targeting CTLA-4, PD-1, PD-L1 pathways), cytokine therapies (such as colony stimulating factors, interferons, interleukins), and oncolytic virus therapies (utilizing adenovirus, herpesvirus, and reovirus).
  • Clinical Indications: Includes hematologic malignancies (ALL, AML, CLL, lymphomas) and solid tumors (breast, lung—addressing both NSCLC and SCLC types, as well as cutaneous and uveal melanoma), each segment requiring tailored approaches to research and commercialization.
  • Administration Routes: Covers intratumoral, intravenous, and subcutaneous delivery modalities, with each route influencing operational models, patient experience, and site-of-care logistics.
  • Care Settings: Spans hospitals, oncology clinics, and specialized centers, each with varying infrastructure capabilities and throughput demands, impacting deployment and adoption strategies.
  • Mechanisms of Action: Involves active immunotherapies (such as vaccines and oncolytic agents), passive immunotherapies (including cell therapies, monoclonal antibodies, and checkpoint modulators), and combination regimens designed for synergistic impact.
  • Geographical Regions: Addresses market dynamics across Americas, EMEA (Europe, Middle East, Africa), and Asia-Pacific, reflecting differences in regulatory pathways, local manufacturing readiness, and adoption speed.

Key Takeaways: Strategic Insights Shaping the Immunotherapy Drugs Market

  • Advanced cellular engineering and antigen design are enabling more precise targeting of new tumor types, increasing the scope of treatment and driving differentiation among therapy developers.
  • Greater regulatory flexibility is streamlining development cycles by fostering adaptive clinical trials and surrogate endpoints, while emphasizing the need for extensive real-world evidence and post-approval validation.
  • Producing cell- and gene-based therapies requires significant capital investment, logistics planning, and scalable manufacturing, prompting organizations to strengthen supplier networks and reinforce cold-chain management.
  • Aligning commercialization with clinical outcomes and operational feasibility is essential, as healthcare payers and providers intensify requirements for demonstrable treatment durability and manageable side effects.
  • Distinct development and market practices prevail: cellular immunotherapies align closely with hematologic cancers, while treating solid tumors demands nuanced antigen selection and delivery innovation due to biological diversity.
  • Regional approaches must address differences in infrastructure, regulatory conditions, and manufacturing capability, particularly as Asia-Pacific accelerates local capacity and European providers navigate complex country-specific processes.

Tariff Impact on Immunotherapy Drugs Supply Chains

Tariffs implemented by the United States in 2025 have introduced new financial and operational pressures for immunotherapy drug manufacturers, notably through higher costs for imported raw materials, laboratory equipment, and essential components used in drug production. In response, companies are:

  • Expanding local and regional production capabilities and fostering domestic supplier networks to mitigate external cost pressures.
  • Leveraging partnerships with contract development and manufacturing organizations (CDMOs) to strengthen supply chain security and reduce delivery timelines.
  • Updating value-based contracting and reimbursement strategies to manage increased commercial risks associated with elevated production costs and global supply chain uncertainty.
  • Enhancing scenario planning and engaging early with payers, regulators, and suppliers to sustain clinical trial schedules and protect ongoing patient access to therapies.

Methodology & Data Sources

This market analysis applies a rigorous, structured approach combining comprehensive literature review, in-depth analysis of clinical data, and primary interviews with leading industry executives, regulators, payers, and pharmacists. Findings are validated through triangulation, expert workshops, and scenario-based risk evaluation to ensure robust, actionable insights.

Why This Report Matters

  • Supports senior decision-makers in recalibrating R&D, manufacturing, regulatory, and go-to-market priorities within a rapidly evolving scientific and policy setting.
  • Presents a detailed, segment-focused framework that identifies strategic opportunities for market entry, regional expansion, and capital allocation.
  • Equips organizations to address operational risks and supply chain vulnerabilities using scenario-driven analysis linked to tariff-induced disruptions.

Conclusion

Leaders in the immunotherapy drugs market are challenged to combine scientific rigor with operational adaptability. Sustained value creation demands comprehensive manufacturing resilience and proactivity as the sector rapidly evolves.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Immunotherapy Drugs Market, by Therapy Type
8.1. Adoptive Cell Therapy
8.1.1. Car-T Therapy
8.1.2. Nk Cell Therapy
8.1.3. Tcr-T Therapy
8.2. Cancer Vaccines
8.2.1. Dendritic Cell Vaccines
8.2.2. Dna Vaccines
8.2.3. Peptide Vaccines
8.3. Checkpoint Inhibitors
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.3.3. Pd-L1 Inhibitors
8.4. Cytokines
8.4.1. Colony Stimulating Factors
8.4.2. Interferons
8.4.3. Interleukins
8.5. Oncolytic Virus Therapy
8.5.1. Adenovirus Based
8.5.2. Herpesvirus Based
8.5.3. Reovirus Based
9. Immunotherapy Drugs Market, by Route Of Administration
9.1. Intratumoral
9.2. Intravenous
9.3. Subcutaneous
10. Immunotherapy Drugs Market, by Mechanism Of Action
10.1. Active Immunotherapy
10.2. Passive Immunotherapy
11. Immunotherapy Drugs Market, by End User
11.1. Hospitals
11.2. Oncology Clinics
11.3. Specialized Centers
12. Immunotherapy Drugs Market, by Indication
12.1. Blood Cancer
12.1.1. Acute Lymphoblastic Leukemia
12.1.2. Acute Myeloid Leukemia
12.1.3. Chronic Lymphocytic Leukemia
12.1.4. Lymphoma
12.2. Breast Cancer
12.2.1. Hormone Receptor Positive
12.2.2. Triple Negative
12.3. Lung Cancer
12.3.1. NonSmallCell Lung Cancer
12.3.2. SmallCell Lung Cancer
12.4. Melanoma
12.4.1. Cutaneous Melanoma
12.4.2. Uveal Melanoma
13. Immunotherapy Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Immunotherapy Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Immunotherapy Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Immunotherapy Drugs Market
17. China Immunotherapy Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Amgen Inc.
18.6. AstraZeneca PLC
18.7. Bristol-Myers Squibb Company
18.8. F. Hoffmann-La Roche Ltd
18.9. Genscript Biotech Corporation
18.10. Gilead Sciences, Inc.
18.11. HD Biosciences Co., Ltd.
18.12. Horizon Discovery Group PLC
18.13. ImmunXperts SA
18.14. Johnson & Johnson
18.15. Jubilant Life Sciences Limited
18.16. Labcorp
18.17. Merck & Co., Inc.
18.18. Novartis AG
18.19. Pfizer Inc.
18.20. Sanofi S.A.
List of Figures
FIGURE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 155. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 156. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 157. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 170. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 171. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 172. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 185. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 186. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 187. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 203. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 205. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 206. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 207. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 208. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 209. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 210. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 212. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 214. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 215. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 216. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 217. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 222. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 223. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 224. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 225. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 229. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 231. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 232. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 233. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 234. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 235. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 236. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 237. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 238. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 239. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 240. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 241. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 242. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 243. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 244. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 245. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 246. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 247. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 248. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 249. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 250. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 251. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 252. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 253. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 254. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 255. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 260. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 261. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 262. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 263. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 264. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 265. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 266. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 267. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 268. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 269. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 270. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 271. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 272. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 273. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 275. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 276. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 277. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 278. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 279. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 280. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 281. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 282. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 283. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 284. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 285. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 286. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 287. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 288. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 289. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 290. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 291. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 292. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 293. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 309. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 310. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 311. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2032 (USD MILLION)
TABLE 312. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
TABLE 313. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 314. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2032 (USD MILLION)
TABLE 315. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
TABLE 316. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 317. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 318. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 319. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 320. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2032 (USD MILLION)
TABLE 321. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2032 (USD MILLION)
TABLE 322. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2032 (USD MILLION)
TABLE 323. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2032 (USD MILLION)
TABLE 324. G7 IMMUNOTHERAPY DRUG

Companies Mentioned

The key companies profiled in this Immunotherapy Drugs market report include:
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genscript Biotech Corporation
  • Gilead Sciences, Inc.
  • HD Biosciences Co., Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Johnson & Johnson
  • Jubilant Life Sciences Limited
  • Labcorp
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

Table Information

Report AttributeDetails
No. of Pages183
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 251.56 Billion
Forecasted Market Value ( USD ) by 2032 $ 543.82 Billion
Compound Annual Growth Rate13.6%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Cancer Immunotherapy Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Cancer Immunotherapy: Technologies and Global Markets - Product Image

Cancer Immunotherapy: Technologies and Global Markets

  • Report
  • 203 Pages
  • Global
From
Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2025 - Product Image

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Cancer Immunotherapy Market Report 2025 - Product Image

Cancer Immunotherapy Market Report 2025

  • Report
  • 250 Pages
  • Global
From

About the Immunotherapy Market

Immunotherapy is a type of treatment used to treat immune disorders, such as allergies, asthma, and autoimmune diseases. It works by stimulating the body's own immune system to fight off disease-causing agents. Immunotherapy drugs are designed to target specific parts of the immune system, such as T-cells, B-cells, and cytokines. These drugs can be used to treat a variety of conditions, including cancer, HIV/AIDS, and rheumatoid arthritis. Immunotherapy drugs are typically administered through injections, infusions, or oral medications. They can also be used in combination with other treatments, such as chemotherapy or radiation therapy. The goal of immunotherapy is to reduce the severity of symptoms and improve the patient's quality of life. The immunotherapy market is a rapidly growing sector of the pharmaceutical industry. Companies in this market are focused on developing new treatments and therapies to treat immune disorders. Some of the major players in this market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.